Organisation paid for research Program year 2022 Source: CMS Open Payments

The Emory Clinic

Neither a doctor nor a teaching hospital

Research payments

$180,144

37 payments

Through program year 2022, The Emory Clinic is reported as receiving $180,144 in research payments, across 37 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$115,620	3
2021	Research	$54,996	3
2020	Research	$1,554	2
2019	Research	$7,973	29

Breakdown

Who paid Research payments · program years 2019–2022

Merck Sharp & Dohme Corporation $123,458 32 payments
Amgen Inc. $56,516 4 payments
Celgene Corporation $170 1 payment

Studies the money was for Research payments · program years 2019–2022

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Aterial Hypertension PAH Therapy for the Treatment of PAH $115,450 2 payments
Phase 2b - SLE Dose-Finding $54,962 2 payments
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients $5,525 3 payments
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients $1,689 25 payments
Phase 2b SLE Dose-Finding $1,554 2 payments
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients $759 1 payment
PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) $170 1 payment
TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy $34 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.